GFH312
/ GenFleet Therap
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
September 06, 2023
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. | N=100 ➔ 0 | Recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Cardiovascular • Peripheral Arterial Disease
August 14, 2023
A Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Healthy Chinese Subjects
(clinicaltrials.gov)
- P1 | N=26 | Completed | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.
New P1 trial
June 22, 2023
A Phase I Randomized, Double-Blinded, Placebo-Controlled Study Assessing the Safety and Pharmacokinetics of RIPK1 Inhibitor GFH312 in Healthy Subjects.
(PubMed, Clin Transl Sci)
- "In conclusion, GFH312 was well tolerated and demonstrated RIPK1 inhibition in healthy subjects. Ongoing studies will inform the use of GFH312 in potential indications."
Clinical • Journal • P1 data • PK/PD data • CNS Disorders • Inflammation • Pain • RIPK1
May 15, 2023
A Study of GFH312 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=76 | Completed | Sponsor: GenFleet Therapeutics (Australia) Pty Ltd. | Recruiting ➔ Completed
Trial completion
April 18, 2023
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Peripheral Arterial Disease
November 16, 2022
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
(clinicaltrials.gov)
- P2 | N=100 | Not yet recruiting | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.
New P2 trial • Cardiovascular • Peripheral Arterial Disease
January 20, 2022
A Study of GFH312 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=88; Recruiting; Sponsor: GenFleet Therapeutics (Australia) Pty Ltd.; Trial completion date: Mar 2022 ➔ Aug 2022; Trial primary completion date: Dec 2021 ➔ May 2022
Clinical • Trial completion date • Trial primary completion date
1 to 7
Of
7
Go to page
1